Form 4: Cytokinetics Director Lynne Parshall Executes Stock Options and Sells Shares

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on August 12, 2024.

Summary

• On August 12, 2024, Lynne Parshall, a director of Cytokinetics Inc., executed non-qualified stock options to purchase 5,000 shares of common stock at a price of $21.61 per share.
• Simultaneously, Ms. Parshall sold 5,000 shares of Cytokinetics common stock at a price of $55.2 per share.
• Following these transactions, Ms. Parshall directly owns 20,600 shares of Cytokinetics common stock and holds options for 10,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It's a routine filing and doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• Shareholders may interpret the transactions as a signal, although single transactions are not necessarily indicative of a trend.

Key Dates